StrataGraft® Skin Tissue as an Alternative to Autografting Deep Partial-Thickness Burns

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01437852
Recruitment Status : Completed
First Posted : September 21, 2011
Last Update Posted : May 24, 2016
Information provided by (Responsible Party):
Stratatech, a Mallinckrodt Company

September 19, 2011
September 21, 2011
May 24, 2016
September 2011
January 2014   (Final data collection date for primary outcome measure)
  • Wound closure of the treatment sites at three months [ Time Frame: 3 months ]
    Determination of complete wound closure of both treatment sites will be evaluated at three months.
  • Percent area of the StrataGraft treatment site requiring autografting by day 28 [ Time Frame: 28 days ]
    The percentage of the treatment site area initially covered with StrataGraft tissue that requires autograft by day 28 will be determined.
Same as current
Complete list of historical versions of study NCT01437852 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
StrataGraft® Skin Tissue as an Alternative to Autografting Deep Partial-Thickness Burns
An Open-Label, Controlled, Randomized, Multicenter, Dose Escalation Study Evaluating the Safety and Efficacy of StrataGraft® Skin Tissue in Promoting the Healing of the Deep Partial-Thickness Component of Complex Skin Defects as an Alternative to Autografting
The proposed study is designed as a phase Ib open-label, dose-escalation, multicenter study evaluating the safety, tolerability, and efficacy of StrataGraft skin tissue in promoting the healing of the deep partial-thickness component of complex skin defects. The proposed study population will include patients with 3-49% Total Body Surface Area (TBSA) complex skin defects including a deep partial-thickness component resulting from thermal injury. The study has been designed to focus on the evaluation of safety and tolerability of prolonged exposure to increasing amounts of a single application of StrataGraft skin tissue, while also assessing the potential for StrataGraft tissue to promote healing of the deep partial-thickness component of these complex skin defects as an alternative to donor site harvesting and autografting. Targeted enrollment for this study is up to 30 patients with complex skin defects due to thermal burns which require surgical excision and autografting. Subjects will be sequentially enrolled in two cohorts of increasing treatment area receiving StrataGraft skin tissue that has been stored refrigerated prior to clinical use. A third cohort will receive StrataGraft skin tissue which has been stored cryopreserved and thawed in the operating room just prior to grafting.
Not Provided
Phase 1
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Skin Wound
  • Burns
  • Trauma-related Wound
Biological: StrataGraft Skin Tissue
StrataGraft® skin tissue is provided as a suturable circular patch of stratified epithelial tissue composed of a living dermal matrix (containing dermal fibroblasts) overlaid with human epidermal keratinocytes (NIKS®).
Experimental: StrataGraft skin tissue
Intervention: Biological: StrataGraft Skin Tissue
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
October 2014
January 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Men and women aged 18-65 years, inclusive
  • Written informed consent
  • Sufficient healthy skin identified and designated as a donor site in the event that the StrataGraft treatment site requires autografting
  • Complex skin defects of 3-49% TBSA requiring excision and autografting
  • Total burn may consist of more than one wound area
  • Deep partial-thickness thermal burn(s) with total area of 88 to 880 cm2 requiring excision and autografting
  • First excision and grafting of treatment sites

Exclusion Criteria:

  • Pregnant women and prisoners
  • Patients receiving systemic immunosuppressive therapy
  • Patients with a known history of malignancy
  • Preadmission insulin-dependent diabetic patients
  • Patients with concurrent conditions that in the opinion of the investigator may compromise patient safety or study objectives
  • Expected survival of less than three months
  • Participation in the treatment group of an interventional study within preceding 90 days prior to enrollment
  • Full-thickness burns will be excluded as treatment sites
  • Chronic wounds will be excluded as treatment sites
  • The face, head, neck, hands, feet, buttocks, and areas over joints will be excluded as treatment sites
  • Treatment sites adjacent to unexcised eschar
  • Clinical suspicion of burn wound infection at the anticipated treatment sites
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
United States
WFUHS 40269 ( Other Grant/Funding Number: AFIRM )
Not Provided
Not Provided
Stratatech, a Mallinckrodt Company
Stratatech, a Mallinckrodt Company
Not Provided
Not Provided
Stratatech, a Mallinckrodt Company
May 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP